Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. (Q54702413)
Jump to navigation
Jump to search
scientific article published on 9 September 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. |
scientific article published on 9 September 2004 |
Statements
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity (English)
Jonathan W Friedberg
Helen Kim
Mary McCauley
Paul Sims
David C Fisher
Robert L Coffman
Arnold S Freedman
9 September 2004